Triamcinolone

Oral
Acquired haemolytic anaemia, Acute rheumatic heart disease, Adjunctive therapy in rheumatic disorders, Allergic and inflammatory conditions of the eye, Allergic conditions, Berylliosis, Congenital adrenal hyperplasia, Congenital hypoplastic anaemia, Crohn's disease, Dermatitis herpetiformis, Diffuse interstitial pulmonary fibrosis, Disseminated pulmonary tuberculosis, Erythema multiforme, Erythroblastopaenia, Exfoliative dermatitis, Fulminant pulmonary tuberculosis, Hypercalcaemia of malignancy, Idiopathic thrombocytopenia, Intractable sprue, Löffler's syndrome, Mycosis fungoides, Non-suppurative thyroiditis, Palliative treatment of leukaemia, Palliative treatment of lymphoma, Pemphigus, Primary adrenocortical insufficiency, Pulmonary emphysema, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Severe psoriasis, Symptomatic sarcoidosis, Systemic lupus erythematosus, Ulcerative colitis

Should be taken with food.

Incompatible with solvents containing phenol, methylparaben, propylparaben.

Idiopathic thrombocytopenic purpura, cerebral malaria; untreated fungal, viral, or bacterial infections; acute psychosis, active TB, herpes simplex keratitis, systemic mycosis and parasitosis.

Patient with glaucoma and/or cataracts, hypertension and/or heart failure, acute MI, diabetes mellitus, gastrointestinal diseases (intestinal anastomoses, diverticulitis, peptic ulcer, ulcerative colitis), cirrhosis, myasthenia gravis, osteoporosis, history of seizure disorder. Avoid abrupt withdrawal. Children. Renal and hepatic impairment. Pregnancy and lactation.

Significant: Adrenal suppression, immunosuppression (e.g. secondary infections, superinfections); kaposi sarcoma, myopathy, psychiatric disturbances including insomnia and depression (parenteral); local topical, nasal or ocular effects (e.g. sensitization, visual disturbances such as increased intraocular pressure, endophthalmitis).
Eye disorders: Cataract (ocular).
Gastrointestinal disorders: Dyspepsia, tooth disorder (nasal).
Injury, poisoning and procedural complications: Injection site reactions (e.g. blurring of vision for ocular, discomfort, pain, erythema, swelling, necrosis, abscess).
Investigations: Elevated blood pressure, weight gain (parenteral).
Metabolism and nutrition disorders: Increased appetite, fluid retention, glucose tolerance alteration (parenteral).
Musculoskeletal and connective tissue disorders: Arthralgia (parenteral).
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Epistaxis (nasal).
Potentially Fatal: Rarely, anaphylaxis.

IM/Intra-articular/Intrabursal/Intradermal/Intralesional/Intrasynovial/Parenteral/SC/Topical: C; Intravitreal: D

Monitor growth and development of child on prolonged therapy.

May antagonise effect of anticholinesterase agent. Additional increase of intraocular pressure with anticholinergics (e.g. atropine). May potentiate or reduce anticoagulant effect of oral anticoagulants. May increase hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of antidiabetics (e.g. sulfonylurea derivatives) and insulin. May diminish arterial blood pressure reduction of antihypertensives (including diuretics). May reduce isoniazid serum concentrations. Increase in both ciclosporin and corticosteroids activity when used concomitantly. May increase toxicity of digitalis glycosides. Increased effects with ketoconazole. May alter the neuromuscular blocking action of non-depolarising muscle relaxants. May increase risk of gastrointestinal bleeding and ulceration associated with NSAIDs. Increased serum levels with oestrogen (including oral contraceptives). Neurological complications and diminished antibody response may occur on vaccinated patients. May develop hypokalaemia with K-depleting agents (e.g. amphotericin B inj, diuretics). May increase risk of QT prolongation or torsade de pointes with class Ia antiarrhythmics (e.g. disopyramide, quinidine, procainamide) or class II antiarrhythmics (e.g. amiodarone, sotalol, bepridil).

May produce false-negative results with nitroblue tetrazolium test for bacterial infection. May produce a positive result in anti-doping test for athletes. May suppress reactions to skin tests.

Description: Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation. It also suppresses the immune system by reducing activity and volume of the lymphatic system.
Pharmacokinetics:
Absorption: Slowly absorbed from inj sites. Time to peak plasma concentration: 8-10 hours (IM).
Distribution: It crosses the placenta. Volume of distribution: 99.5 L. Plasma protein binding: Approx 68%.
Excretion: Via urine (approx 40%); faeces (approx 60%). Plasma half-life: Approx 2-5 hours.

Source: National Center for Biotechnology Information. PubChem Database. Triamcinolone, CID=31307, https://pubchem.ncbi.nlm.nih.gov/compound/Triamcinolone (accessed on Jan. 23, 2020)

Store between 20-25°C. Do not freeze. Protect from light.

Corticosteroid Hormones / Eye Corticosteroids / Preparations for Oral Ulceration & Inflammation / Topical Corticosteroids

D07AB09 - triamcinolone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
A01AC01 - triamcinolone ; Belongs to the class of local corticosteroid preparations. Used in the treatment of diseases of the mouth.
S01BA05 - triamcinolone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
R01AD11 - triamcinolone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
D07XB02 - triamcinolone ; Belongs to the class of moderately potent (group II) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
C05AA12 - triamcinolone ; Belongs to the class of products containing corticosteroids for topical use. Used in the treatment of hemorrhoids and anal fissures.
H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
R03BA06 - triamcinolone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.

Anon. Triamcinolone (Nasal). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/01/2016.

Anon. Triamcinolone (Ophthalmic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/01/2016.

Anon. Triamcinolone (Systemic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/01/2016.

Anon. Triamcinolone (Topical). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/01/2016.

Anon. Triamcinolone Acetonide (EENT). AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 05/01/2016.

Anon. Triamcinolone Acetonide (Topical). AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 05/01/2016.

Anon. Triamcinolone, Triamcinolone Acetonide, Triamcinolone Hexacetonide. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 05/01/2016.

Buckingham R (ed). Triamcinolone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/01/2016.

Joint Formulary Committee. Triamcinolone Acetonide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/01/2016.

Joint Formulary Committee. Triamcinolone Hexacetonide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/01/2016.

Kenacort (Taisho Pharmaceutical). MIMS Indonesia. http://www.mims.com/indonesia. Accessed 10/07/2018.

Kenalog-10 Injection and Kenalog-40 Injection. U.S. FDA. https://www.fda.gov/. Accessed 05/01/2016.

Nasacort Aerosol, Metered (Aventis Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/01//2016.

Triamcinolone Acetonide Cream (Arbor Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/01//2016.

Triamcinolone Acetonide Injection, Suspension (Sandoz Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/01//2016.

Triesence Injection (Alcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/01//2016.